INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0

Q3 2021 13F Holders as of 30 Sep 2021

Type / Class
Debt / NOTE 3.250% 7/0
Market price (% of par)
90.18%
Total 13F principal
$84,114,142
Principal change
-$327,209,137
Total reported market value
$77,029,805
Number of holders
26
Value change
-$293,537,003
Number of buys
6
Number of sells
18

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2021

As of 30 Sep 2021, INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by 26 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $84,114,142 in principal (par value) of the bond. The largest 10 bondholders included DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), MORGAN STANLEY, CALAMOS ADVISORS LLC, BlackRock Inc., Saltoro Capital, LP, STATE STREET CORP, Shaolin Capital Management LLC, ZAZOVE ASSOCIATES LLC, Parallax Volatility Advisers, L.P., and L & S Advisors Inc. This page lists 26 institutional bondholders reporting positions for the Q3 2021 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.